These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34241685)

  • 61. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi.
    Dellabella M; Milanese G; Muzzonigro G
    J Urol; 2005 Jul; 174(1):167-72. PubMed ID: 15947613
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparative study of extracorporeal shock wave lithotripsy outcomes for proximal and distal ureteric stones.
    Turna B; Akbay K; Ekren F; Nazli O; Apaydin E; Semerci B; Günaydin G; Cüreklibatir I
    Int Urol Nephrol; 2008; 40(1):23-9. PubMed ID: 17647086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Alpha-blockers as medical expulsive therapy for ureteral stones.
    Campschroer T; Zhu X; Vernooij RW; Lock MT
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008509. PubMed ID: 29620795
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: A randomized crossover study (the MICRO study).
    Torimoto K; Matsushita C; Yamada A; Goto D; Matsumoto Y; Hosokawa Y; Miyake M; Aoki K; Hirayama A; Tanaka N; Fujimoto K
    Neurourol Urodyn; 2017 Apr; 36(4):1097-1103. PubMed ID: 27265880
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tamsulosin hydrochloride vs placebo for management of distal ureteral stones: a multicentric, randomized, double-blind trial.
    Vincendeau S; Bellissant E; Houlgatte A; Doré B; Bruyère F; Renault A; Mouchel C; Bensalah K; Guillé F;
    Arch Intern Med; 2010 Dec; 170(22):2021-7. PubMed ID: 21149761
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mirabegron (Myrbetriq) for overactive bladder.
    Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
    [No Abstract]   [Full Text] [Related]  

  • 68. Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study).
    Kumar S; Jayant K; Agrawal MM; Singh SK; Agrawal S; Parmar KM
    Urology; 2015 Jan; 85(1):59-63. PubMed ID: 25530364
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
    Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
    Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does tamsulosin or mirabegron improve ureteral stent-related symptoms? A prospective placebo-controlled study.
    Yavuz A; Kilinc MF; Aydin M; Ofluoglu Y; Bayar G
    Low Urin Tract Symptoms; 2021 Jan; 13(1):17-21. PubMed ID: 32408390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Silodosin versus Tamsulosin as Medical Expulsive Therapy for Children with Lower-Third Ureteric Stones: Prospective Randomized Placebo-Controlled Study.
    Soliman MG; El-Gamal O; El-Gamal S; Abdel Raheem A; Abou-Ramadan A; El-Abd A
    Urol Int; 2021; 105(7-8):568-573. PubMed ID: 33524970
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
    Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
    Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones.
    Sun X; He L; Ge W; Lv J
    J Urol; 2009 Apr; 181(4):1716-20. PubMed ID: 19233432
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Efficacy of tamsulosin in medical expulsive therapy for distal ureteral calculi.
    Sayed MA; Abolyosr A; Abdalla MA; El-Azab AS
    Scand J Urol Nephrol; 2008; 42(1):59-62. PubMed ID: 17853008
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of Silodosin Dose in Medical Expulsive Therapy for Distal Ureteral Stones: A Retrospective Study.
    Yuceturk CN; Dadali M; Bagbanci MS; Ozgur BC; Aydogmus Y; Yildiz Y; Kilinc MF
    Urol J; 2017 Jan; 14(1):2944-2948. PubMed ID: 28116737
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi.
    El-Gamal O; El-Bendary M; Ragab M; Rasheed M
    Urol Res; 2012 Jun; 40(3):219-24. PubMed ID: 21858663
    [TBL] [Abstract][Full Text] [Related]  

  • 78. External physical vibration lithecbole facilitating the expulsion of upper ureteric stones 1.0-2.0 cm after extracorporeal shock wave lithotripsy: a prospective randomized trial.
    Tao RZ; Tang QL; Zhou S; Jia CP; Lv JL
    Urolithiasis; 2020 Feb; 48(1):71-77. PubMed ID: 30488093
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
    Balachandran A; Curtiss N; Basu M; Duckett J
    Int Urogynecol J; 2015 Mar; 26(3):367-72. PubMed ID: 25030325
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder.
    Chapple CR; Nitti VW; Khullar V; Wyndaele JJ; Herschorn S; van Kerrebroeck P; Blauwet MB; Siddiqui E
    World J Urol; 2014 Dec; 32(6):1565-72. PubMed ID: 24458878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.